Access to molecular diagnostics for CNS tumors through international outsourcing: experience from Jordan
-
By
-
Ruba Al Abweh
-
Sarah Al Sharie
-
Nabil Hasasna
-
Nisreen Amayiri
-
Mouness Obeidat
-
Maysa Al-Hussaini
-
July 17, 2026
Clinical Scorecard: International Outsourcing of Molecular Diagnostics for CNS Tumors: Insights from Jordan's Experience
At a Glance
| Category | Detail |
|---|
| Condition | Central Nervous System Tumors |
| Key Mechanisms | Molecular profiling for diagnosis, risk stratification, and treatment |
| Target Population | Pediatric and adult patients with CNS tumors |
| Care Setting | Limited-resource settings |
Key Highlights
- Outsourced molecular testing yielded conclusive results in 92% of cases.
- Median turnaround time for testing was 26 days.
- Actionable therapeutic targets identified in 27% of tumors.
- Molecular testing led to a change in diagnosis in 4% of cases.
- Study involved 105 patients, predominantly pediatric (87%).
Guideline-Based Recommendations
Diagnosis
- Molecular profiling is essential for defining tumor type, grade, and prognosis.
Management
- Molecular testing informs treatment decisions and risk stratification.
Monitoring & Follow-up
- Regular assessment of molecular diagnostics to ensure access and accuracy.
Risks
- Limited access to molecular diagnostics can lead to incomplete diagnoses and missed treatment opportunities.
Patient & Prescribing Data
Patients with CNS tumors at King Hussein Cancer Center in Jordan.
Identification of targetable alterations can guide therapy, particularly in low-grade and high-grade gliomas.
Clinical Best Practices
- Consider outsourcing molecular diagnostics in resource-limited settings to improve access.
- Integrate molecular profiling into routine diagnostic workflows for CNS tumors.
Related Resources & Content
